These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 31203420)

  • 1. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI.
    Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
    Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
    Bashir A; Brennum J; Broholm H; Law I
    J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2257-2265. PubMed ID: 28831534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiparametric Analysis Combining DSC-MR Perfusion and [18F]FET-PET is Superior to a Single Parameter Approach for Differentiation of Progressive Glioma from Radiation Necrosis.
    Panholzer J; Malsiner-Walli G; Grün B; Kalev O; Sonnberger M; Pichler R
    Clin Neuroradiol; 2024 Jun; 34(2):351-360. PubMed ID: 38157019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
    Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
    Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Maurer GD; Brucker DP; Stoffels G; Filipski K; Filss CP; Mottaghy FM; Galldiks N; Steinbach JP; Hattingen E; Langen KJ
    J Nucl Med; 2020 Apr; 61(4):505-511. PubMed ID: 31519802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.
    Rahm V; Boxheimer L; Bruehlmeier M; Berberat J; Nitzsche EU; Remonda L; Roelcke U
    J Nucl Med; 2014 Apr; 55(4):546-50. PubMed ID: 24566001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential implementation of DSC-MR perfusion and dynamic [
    Steidl E; Langen KJ; Hmeidan SA; Polomac N; Filss CP; Galldiks N; Lohmann P; Keil F; Filipski K; Mottaghy FM; Shah NJ; Steinbach JP; Hattingen E; Maurer GD
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1956-1965. PubMed ID: 33241456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
    Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
    Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.
    Albert NL; Winkelmann I; Suchorska B; Wenter V; Schmid-Tannwald C; Mille E; Todica A; Brendel M; Tonn JC; Bartenstein P; la Fougère C
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1105-14. PubMed ID: 26666239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
    Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multimodal and integrative 18F-FET PET/fast-DKI approach.
    Lohmeier J; Radbruch H; Brenner W; Hamm B; Hansen B; Tietze A; Makowski MR
    Eur Radiol; 2024 Apr; 34(4):2487-2499. PubMed ID: 37672058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Treatment Response Assessment Using
    Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of
    Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of O-(2-
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression.
    Müller M; Winz O; Gutsche R; Leijenaar RTH; Kocher M; Lerche C; Filss CP; Stoffels G; Steidl E; Hattingen E; Steinbach JP; Maurer GD; Heinzel A; Galldiks N; Mottaghy FM; Langen KJ; Lohmann P
    J Neurooncol; 2022 Sep; 159(3):519-529. PubMed ID: 35852737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.